SANUWAVE Health (SNWV)

The company’s main commercial platform is UltraMIST, an FDA-cleared system used in the treatment of acute and chronic wounds. UltraMIST delivers low-frequency ultrasound through a saline mist, allowing energy to be applied without direct contact with the wound surface. The system is designed for clinical settings where providers manage complex wounds such as diabetic foot ulcers, venous leg ulcers, pressure injuries, and other hard-to-heal tissue damage.

SANUWAVE operates in the wound care market, a healthcare segment shaped by ageing populations, diabetes prevalence, vascular disease, and the need to reduce complications that can lead to infection, hospitalization, or amputation. Its technology is positioned as an adjunctive therapy, meaning it can be used alongside standard wound care protocols such as debridement, dressings, infection control, and offloading.

The company reports its activities primarily as the design and sale of medical devices, with revenue generated mainly in the United States. Its commercial prospects depend on adoption by wound care clinics, hospitals, long-term care providers, and other healthcare practitioners, as well as reimbursement, clinical evidence, distribution reach, and device utilization. As a smaller medical device company, SANUWAVE’s performance is particularly sensitive to sales execution, regulatory compliance, capital availability, and competitive dynamics in advanced wound care.